DOCSLIB.ORG

Guidelines for Oesophageal Manometry and Ph Monitoring 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines for Oesophageal Manometry and Ph Monitoring 1 Guidelines for oesophageal manometry and pH monitoring 1 Guidelines for oesophageal manometry and pH monitoring Keith Bodger1 and Nigel Trudgill2 1 Aintree Centre for Gastroenterology, University Hospital Aintree, Liverpool, L9 7AL 2 Department of Gastroenterology, Sandwell General Hospital, Lyndon, West Bromwich, West Midlands, B71 4HJ EXECUTIVE SUMMARY & RECOMMENDATIONS tion for their symptoms. A high dose therapeutic trial of a pro- n patients with suspected oesophageal symptoms, flexible ton pump inhibitor is indicated in such patients (Evidence endoscopy and/or contrast radiology (eg. barium swallow) grade B). In patients with throat or respiratory symptoms Ishould be performed before considering manometric this trial should be for four months, as a symptomatic assessment (Evidence grade C). response may be delayed (Evidence grade B). Ambulatory Oesophageal manometry is indicated for the evaluation of oesophageal pH monitoring off therapy may be of value to dysphagia not definitively diagnosed by means of endoscopy exclude excess acid gastro-oesophageal reflux when this and/or radiology, as manometry is the most accurate method appears unlikely or pH monitoring on a proton pump inhibitor for diagnosing the well-characterised primary oesophageal may be of value when there is an inadequate response to a motility disorders (achalasia and diffuse oesophageal spasm) therapeutic trial, to judge whether further dose escalation is (Evidence grade C). appropriate (Evidence grade C). Oesophageal manometry is the most accurate method for Patients with endoscopic oesophagitis and a good response pH electrode placement (Evidence grade B). to a proton pump inhibitor do not require an ambulatory Acid gastro-oesophageal reflux accounts for a significant oesophageal pH study prior to anti-reflux surgery. Patients proportion of non-specific manometric abnormalities and a with symptoms suggestive of acid reflux without endoscopic therapeutic trial of a proton pump inhibitor is recommended oesophagitis and a good response to a proton pump inhibitor in the initial management of patients with suspected should undergo ambulatory oesophageal pH monitoring off oesophageal symptoms, who have non-specific motility therapy prior to anti-reflux surgery (Evidence grade abnormalities identified at manometry (Evidence grade C) C).Patients with symptoms potentially due to acid reflux who Pre-operative oesophageal manometry is of limited value fail to respond to a high dose proton pump inhibitor should but does prevent anti-reflux surgery in the rare patients who undergo ambulatory oesophageal pH monitoring on a proton present with clinical features suggestive of acid gastro- pump inhibitor prior to anti-reflux surgery and a good corre- oesophageal reflux and have a primary motility disorder, such lation between the patient’s symptoms and acid reflux as achalasia, and is therefore recommended (Evidence grade episodes, as assessed by the symptom index, established C). (Evidence grade C). Ambulatory oesophageal pH monitor- In the absence of locally determined ranges for defining the ing should be undertaken in patients with persistent limits of physiological acid reflux, the following data should symptoms following anti-reflux surgery, particularly if further be utilised: percentage total time oesophageal pH<4 <5%; surgery is planned, to ensure there is evidence of persistent percentage upright time oesophageal pH<4 <8%; percentage acid reflux and a good correlation between the patient’s supine time oesophageal pH<4 <3%; number of episodes symptoms and acid reflux episodes (Evidence grade C). pH<4 for >5 minutes <3 (Evidence grade B). Oesophageal manometry and ambulatory oesophageal pH Ambulatory oesophageal pH monitoring has clear limita- monitoring are associated with minor morbidity, largely vaso- tions in defining pathological acid reflux due to false negative vagal episodes, discomfort from the catheter and a runny studies, but it is the only investigation that provides informa- nose, and restrictions affecting diet and activity. Patients with tion on whether patients’ symptoms are related to acid reflux. a heart valve replacement or a previous episode of bacterial The optimal period for analysis is from two minutes before to endocarditis should receive antibiotic prophylaxis (Evidence the time the event marker on the data logger was pressed grade C). All patients undergoing oesophageal manometry or (Evidence grade B). A measure of the association of the ambulatory oesophageal pH monitoring should give written patient’s symptoms and acid reflux episodes, such as the informed consent (Evidence grade C). symptom index, and the number of symptomatic events, To ensure high clinical standards in oesophageal function should be included in the report of an ambulatory testing, all clinicians undertaking oesophageal manometry or oesophageal pH study (Evidence grade C). pH monitoring in the United Kingdom should be registered Ambulatory oesophageal pH monitoring has no role in the with the Association of Gastrointestinal Physiologists (AGIP) initial management of patients with symptoms suggestive of (Evidence grade C). acid gastro-oesophageal reflux. A high dose therapeutic trial of a proton pump inhibitor is the diagnostic investigation of 1.0 INTRODUCTION choice (Evidence grade B). In patients with symptoms sug- Oesophageal disorders are among the most common medical gestive of acid gastro-oesophageal reflux, who fail to respond conditions. Symptoms of acid gastro-oesophageal reflux affect during a therapeutic trial of a proton pump inhibitor, ambula- up to a third of the population in the UK. Oesophageal tory oesophageal pH monitoring on a proton ump inhibitor manometry and ambulatory oesophageal pH monitoring have may be of value to obviate the need for repeated, potentially become established clinical tools in the investigation of futile, attempts at dose escalation (Evidence grade C). oesophageal symptoms. There have been significant develop- Chest pain, throat and respiratory symptoms may be due to ments in this field since the previous guidelines were acid gastro-oesophageal reflux, particularly in patients with formulated in 1996, particularly the advent of proton pump heartburn or acid regurgitation and no alternative explana- inhibitors and increasing awareness of the value of therapeu- November 2006 BSG Guidelines in Gastroenterology 2 Keith Bodger and Nigel Trudgill tic trials with these agents. These developments merit a comprises a pressure sensing apparatus that detects changes reassessment of the clinical role of oesophageal manometry in luminal pressure and converts this to an electrical signal, and ambulatory oesophageal pH monitoring and this is the and a recording device that amplifies and stores this informa- purpose of these guidelines. tion for subsequent analysis. Manometric results are presented either as hard copy readouts (using ink or thermal 2.0 FORMULATION OF GUIDELINES writing polygraphs) or via computer-generated reporting These guidelines have been produced in accordance with rec- using analog to digital conversion and software analysis. ommendations of the North of England evidence based guidelines development project.i They are based on a Medline There are two main forms of sensing/transducer device in literature search using the search terms “oesophageal current use: manometry” and “oesophageal pH monitoring”, and on expert opinion and review. The application of oesophageal Water-perfused catheters coupled to volume-displacement studies in the paediatric population is considered beyond the transducers scope of these guidelines. This type of catheter comprises a bundle of thin plastic tubes each with an outward facing side-hole. There are typically 3- 2.1 CATEGORIES OF EVIDENCE 8 pressure-sensing side holes spaced along the length of the The strength of evidence used to formulate these guidelines catheter and radially orientated, thereby allowing simultane- was graded according to the following system: ous measurement of pressures at multiple locations. The tubes are continuously perfused with bubble-free water as a • Ia—Evidence obtained from meta-analysis of randomised non-compressible medium and the pressure in each tube is controlled trials. monitored by a volume-displacement transducer. Water flow • Ib—Evidence obtained from at least one randomised through the side holes is impeded by oesophageal contraction. controlled trial. • IIa—Evidence obtained from at least one well designed Solid-state strain gauges controlled study without randomisation. This type of catheter is composed of a linear arrangement of • IIb—Evidence obtained from at least one other type of well miniature, solid-state strain gauges spatially and radially ori- designed quasi experimental study. entated along a flexible tube. The signal from each strain • III—Evidence obtained from well designed non- gauge provides a direct measure of intraluminal pressure. experimental descriptive studies such as comparative These catheters are technically easier to use and less cumber- studies, correlation studies, and case studies. some than traditional water-perfused systems, but are more • IV—Evidence obtained from expert committee reports or expensive both to buy and repair. There have been no studies opinions, or clinical experiences of respected authorities. to compare the relative running costs of the two alternative systems. Absolute pressure values and normal ranges The evidence category is indicated after the citations in the obtained with water-perfused
Load more

Recommended publications
  • Peptic Ulcer Disease
    Peptic Ulcer Disease orking with you as a partner in health care, your gastroenterologist Wat GI Associates will determine the best diagnostic and treatment measures for your unique needs. Albert F. Chiemprabha, M.D. Pierce D. Dotherow, M.D. Reed B. Hogan, M.D. James H. Johnston, III, M.D. Ronald P. Kotfila, M.D. Billy W. Long, M.D. Paul B. Milner, M.D. Michelle A. Petro, M.D. Vonda Reeves-Darby, M.D. Matt Runnels, M.D. James Q. Sones, II, M.D. April Ulmer, M.D., Pediatric GI James A. Underwood, Jr., M.D. Chad Wigington, D.O. Mark E. Wilson, M.D. Cindy Haden Wright, M.D. Keith Brown, M.D., Pathologist Samuel Hensley, M.D., Pathologist Jackson Madison Vicksburg 1421 N. State Street, Ste 203 104 Highland Way 1815 Mission 66 Jackson, MS 39202 Madison, MS 39110 Vicksburg, MS 39180 Telephone 601/355-1234 • Fax 601/352-4882 • 800/880-1231 www.msgastrodocs.com ©2010 GI Associates & Endoscopy Center. All rights reserved. A discovery that Table of contents brought relief to millions of ulcer What Is Peptic Ulcer Disease............... 2 patients...... Three Major Types Of Peptic Ulcer Disease .. 6 The bacterium now implicated as a cause of some ulcers How Are Ulcers Treated................... 9 was not noticed in the stomach until 1981. Before that, it was thought that bacteria couldn’t survive in the stomach because Questions & Answers About Peptic Ulcers .. 11 of the presence of acid. Australian pathologists, Drs. Warren and Marshall found differently when they noticed bacteria Ulcers Can Be Stubborn................... 13 while microscopically inspecting biopsies from stomach tissue.
    [Show full text]
  • EGD - If You Have Symptoms That Do Not Go Away, Like Heartburn, Vomiting Or Belly Pain, You May Need an Upper Endoscopy
    EGD - if you have symptoms that do not go away, like heartburn, vomiting or belly pain, you may need an upper endoscopy. An upper endoscopy is also known as an esophagogastroduodenoscopy (EGD). It is a test that enables doctors to examine the upper digestive tract, which includes the: • Esophagus (“food tube” that connects the mouth to the stomach) • Stomach • Duodenum (upper part of the small intestine) An EGD uses an endoscope, which is a long, flexible tube with a camera and light at its tip. The doctor carefully guides the endoscope through the mouth and down the throat to view the upper digestive tract to view images of the digestive tract and can take color photos of specific areas. They may take a biopsy (tissue sample) of abnormal tissue, such as growths, irritations or ulcers, which are sores in the intestine’s lining. Esophageal dilation - Esophageal dilation is a procedure that allows your doctor to dilate, or stretch, a narrowed area of your esophagus [swallowing tube]. Doctors can use various techniques for this procedure while your are sedated during your EGD. Flexible Sigmoidoscopy - A sigmoidoscope is a slender, flexible tube with a light and a very small video camera at the end of it. It is shorter than a colonoscope and is only able to evaluate the lower third of the colon. This allows a look at the inside of the rectum and lower part of the colon for cancer or polyps. Before the test, you will need to take an enema or other prep to clean out the lower colon, but a full cleansing solution is not needed as in colonoscopy.
    [Show full text]
  • Abdominal Pain - Gastroesophageal Reflux Disease
    ACS/ASE Medical Student Core Curriculum Abdominal Pain - Gastroesophageal Reflux Disease ABDOMINAL PAIN - GASTROESOPHAGEAL REFLUX DISEASE Epidemiology and Pathophysiology Gastroesophageal reflux disease (GERD) is one of the most commonly encountered benign foregut disorders. Approximately 20-40% of adults in the United States experience chronic GERD symptoms, and these rates are rising rapidly. GERD is the most common gastrointestinal-related disorder that is managed in outpatient primary care clinics. GERD is defined as a condition which develops when stomach contents reflux into the esophagus causing bothersome symptoms and/or complications. Mechanical failure of the antireflux mechanism is considered the cause of GERD. Mechanical failure can be secondary to functional defects of the lower esophageal sphincter or anatomic defects that result from a hiatal or paraesophageal hernia. These defects can include widening of the diaphragmatic hiatus, disturbance of the angle of His, loss of the gastroesophageal flap valve, displacement of lower esophageal sphincter into the chest, and/or failure of the phrenoesophageal membrane. Symptoms, however, can be accentuated by a variety of factors including dietary habits, eating behaviors, obesity, pregnancy, medications, delayed gastric emptying, altered esophageal mucosal resistance, and/or impaired esophageal clearance. Signs and Symptoms Typical GERD symptoms include heartburn, regurgitation, dysphagia, excessive eructation, and epigastric pain. Patients can also present with extra-esophageal symptoms including cough, hoarse voice, sore throat, and/or globus. GERD can present with a wide spectrum of disease severity ranging from mild, intermittent symptoms to severe, daily symptoms with associated esophageal and/or airway damage. For example, severe GERD can contribute to shortness of breath, worsening asthma, and/or recurrent aspiration pneumonia.
    [Show full text]
  • Gastroenterology, Nutrition and Organ Transplantation
    Gastroenterology, Nutrition and Organ Transplantation MEDICAL POLICY GROUP Co-chairs Katherine Dallow, MD, MPH • Vice President • Clinical Programs and Strategy Desiree Otenti, ANP, MPH, Senior Director • Medical Policy Administration October 27th 2020 12-2 pm Conference call only. Please email [email protected] for more information. Invited: Katherine Dallow, MD, MPH, co-chair (Medical Policy Administration), Desiree Otenti, ANP, co- chair, (Medical Policy Administration); Grace Baker, MSW, LCSW, (Medical Policy Administration); Laura Barry, RN, BSN, (Medical Policy Administration); Craig Haug, MD, (Surgery); Thomas Hawkins, MD, (Internal Medicine); Kenneth Duckworth, MD, (Psychiatry); Peter Lakin, R.Ph, (Pharmacy Operations); Thomas Kowalski, R.Ph, (Clinical Pharmacy) Invited Physician Guest(s): Representatives from the Massachusetts Society of Gastroenterology; Massachusetts Society of Organ Transplantation Policies with Upcoming Coverage Updates Transcatheter Arterial Effective 12/1/2020: Chemoembolization to Treat New investigational indications described for TACE as part of combination Primary or Metastatic Liver therapy (with radiofrequency ablation) for resectable or unresectable Malignancies (634) hepatocellular carcinoma. Policies with Coverage Updates in the Past 12 Months AIM guideline: Effective August 16, 2020: Advanced Vascular Imaging Aneurysm of the abdominal aorta or iliac arteries (930) • Added new indication for asymptomatic enlargement by imaging • Clarified surveillance intervals for stable aneurysms as follows: o Treated
    [Show full text]
  • Esophageal Functional Disorders in the Pre-Operatory Evaluation of Bariatric Surgery
    AG-2020-213 ORIGINAL ARTICLE doi.org/10.1590/S0004-2803.202100000-34 Esophageal functional disorders in the pre-operatory evaluation of bariatric surgery Eponina Maria de Oliveira LEMME1, Angela Cerqueira ALVARIZ2 and Guilherme Lemos Cotta PEREIRA3 Received: 28 September 2020 Accepted: 11 December 2020 ABSTRACT – Background – Obesity is an independent risk factor for esophageal symptoms, gastroesophageal reflux disease (GERD), and motor ab- normalities. When contemplating bariatric surgery, patients with obesity type III undergo esophagogastroduodenoscopy (EGD) and also esophageal manometry (EMN), and prolonged pHmetry (PHM) as part of their pre-operative evaluation. Objective – Description of endoscopy, manometry and pHmetry findings in patients with obesity type III preparing for bariatric surgery, and correlation of these findings with the presence of typical GERD symptoms. Methods – Retrospective study in which clinical symptoms of GERD were assessed, focusing on the presence of heartburn and regurgitation. All patients underwent EMN, PHM and most of them EGD. Results – 114 patients (93 females–81%), average age 36 years old, average BMI of 45.3, were studied. Typical GERD symptoms were referred by 43 (38%) patients while 71 (62%) were asymptomatic. Eighty two patients (72% of total) underwent EGD and 36 (42%) evidenced esophageal abnormalities. Among the abnormal findings, hiatal hernia was seen in 36%, erosive esophagitis (EE) in 36%, and HH+EE in 28%. An abnormal EMN was recorded in 51/114 patients (45%). The main abnormality was a hypotensive lower esophageal sphincter (LES) in 32%, followed by ineffective esophageal motility in 25%, nutcracker esophagus in 19%, IEM + hypotensive LES in 10%, intra-thoracic LES (6%), hypertensive LES (4%), aperistalsis (2%) and achalasia (2%).
    [Show full text]
  • Esophageal Ph Monitoring
    MEDICAL POLICY POLICY TITLE ESOPHAGEAL PH MONITORING POLICY NUMBER MP-2.017 Original Issue Date (Created): 7/1/2002 Most Recent Review Date (Revised): 3/04/2021 Effective Date: 7/1/2021 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY I. POLICY Esophageal pH monitoring using a wireless or catheter-based system may be considered medically necessary for the following clinical indications in adults and children or adolescents able to report symptoms*: Documentation of abnormal acid exposure in endoscopy-negative patients being considered for surgical antireflux repair; Evaluation of patients after antireflux surgery who are suspected of having ongoing abnormal reflux; Evaluation of patients with either normal or equivocal endoscopic findings and reflux symptoms that are refractory to proton pump inhibitor therapy; Evaluation of refractory reflux in patients with chest pain after cardiac evaluation and after a 1-month trial of proton pump inhibitor therapy; Evaluation of suspected otolaryngologic manifestations of gastroesophageal reflux disease (i.e., laryngitis, pharyngitis, chronic cough) in patients that have failed to respond to at least 4 weeks of proton pump inhibitor therapy; Evaluation of concomitant gastroesophageal reflux disease in an adult-onset, nonallergic asthmatic suspected of having reflux-induced asthma. *Esophageal pH monitoring systems should be used in accordance with FDA-approved indications and age ranges. Twenty-four-hour esophageal pH monitoring (standard catheter-based) may be considered medically necessary in infants or children who are unable to report or describe symptoms of reflux with any of the following: Unexplained apnea; Bradycardia; Refractory coughing or wheezing, stridor, or recurrent choking (aspiration); Page 1 MEDICAL POLICY POLICY TITLE ESOPHAGEAL PH MONITORING POLICY NUMBER MP-2.017 Persistent or recurrent laryngitis; and Recurrent pneumonia.
    [Show full text]
  • Pediatric Gastroesophageal Reflux Clinical Practice Guidelines 499
    Journal of Pediatric Gastroenterology and Nutrition 49:498–547 # 2009 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Co-Chairs: ÃYvan Vandenplas and yColin D. Rudolph Committee Members: zCarlo Di Lorenzo, §Eric Hassall, jjGregory Liptak, ôLynnette Mazur, #Judith Sondheimer, ÃÃAnnamaria Staiano, yyMichael Thomson, zzGigi Veereman-Wauters, and §§Tobias G. Wenzl ÃUZ Brussel Kinderen, Brussels, Belgium, {Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children’s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, USA, {Division of Pediatric Gastroenterology, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH, USA, §Division of Gastroenterology, Department of Pediatrics, British Columbia Children’s Hospital/University of British Columbia, Vancouver, BC, Canada, jjDepartment of Pediatrics, Upstate Medical University, Syracuse, NY, USA, ôDepartment of Pediatrics, University of Texas Health Sciences Center Houston and Shriners Hospital for Children, Houston, TX, USA, #Department of Pediatrics, University of Colorado Health Sciences Center, Denver, CO, USA, ÃÃDepartment of Pediatrics, University of Naples
    [Show full text]
  • Selecthealth Medical Policies Gastroenterology Policies
    SelectHealth Medical Policies Gastroenterology Policies Table of Contents Policy Title Policy Last Number Revised Bravo PH Monitoring Probe 200 12/19/09 Colonic Manometry 619 10/02/17 Computed Tomography Colonography (CTC) Virtual Colonoscopy 399 04/22/10 DNA Analysis of Stool for Colon Cancer Screening (Cologuard) 260 09/16/21 Drug Monitoring in Inflammatory Bowel Disease 532 02/26/20 Endoscopic Ultrasonography (EUS) 118 05/31/16 Formulas And Other Enteral Nutrition 534 12/21/20 Gastric Pacing/Gastric Electrical Stimulation (GES) 585 05/27/20 Genetic Testing: CA 19-9 Testing 331 06/30/16 IB-Stim 637 10/14/19 Injectable Bulking Agents In The Treatment Of Fecal Incontinence 531 06/10/15 In-Vivo Detection of Mucosal Lesions with Endoscopy 574 10/15/15 LINX System For The Management of Gerd 520 01/28/13 Peroral Endoscopic Myotomy (POEM) for the Treatment of 588 06/06/16 Esophageal Achlasia Pillcam ESO (Esophagus) 278 08/18/08 Prognostic Serogenetic Testing for Crohn’s Disease (Prometheus® Monitr™) 484 04/06/21 Serologic Testing For Diagnosis of Inflammatory Bowel Disease 175 04/06/21 Serum Testing For Hepatic Fibrosis (Fibrospect II, The Fibrotest, and The 274 08/28/20 HCV-Fibrosure Test) Transcutaneous Electrical Stimulation Devices For Nausea and Vomiting 199 12/27/09 Transendoscopic Anti-Reflux Procedures 198 08/06/10 By accessing and/or downloading SelectHealth policies, you automatically agree to the Medical and Coding/ Reimbursement Policy Manual Terms and Conditions. Gastroenterology Policies, Continued MEDICAL POLICY BRAVO PH MONITORING PROBE Policy # 200 Implementation Date: 10/10/03 Review Dates: 11/18/04, 9/7/05, 12/21/06, 12/20/07, 12/18/08, 12/16/10, 12/15/11, 4/12/12, 6/20/13, 4/17/14, 5/7/15, 4/14/16, 4/27/17, 6/24/18, 4/23/19, 4/6/20 Revision Dates: 12/19/09 Disclaimer: 1.
    [Show full text]
  • Laparoscopic Antireflux Surgery After Roux-En-Y Gastric Bypass for Obesity
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Biblioteca Digital da Produção Intelectual da Universidade de São Paulo (BDPI/USP) Universidade de São Paulo Biblioteca Digital da Produção Intelectual - BDPI Sem comunidade Scielo 2012 Modified Nissen fundoplication: laparoscopic antireflux surgery after Roux-en-Y gastric bypass for obesity Clinics,v.67,n.5,p.531-533,2012 http://www.producao.usp.br/handle/BDPI/40389 Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo CLINICS 2012;67(5):531-533 DOI:10.6061/clinics/2012(05)23 CASE REPORT Modified Nissen fundoplication: laparoscopic anti- reflux surgery after Roux-en-Y gastric bypass for obesity Nilton T Kawahara,I Clarissa Alster,I Fauze Maluf-Filho,II Wilson Polara,III Guilherme M. Campos,IV Luiz Francisco Poli-de-Figueiredo (in memoriam)I I Faculdade de Medicina da Universidade de Sa˜ o Paulo, (FMUSP), Department of Surgical Technique, Sa˜ o Paulo/SP, Brazil. II Faculdade de Medicina da Universidade de Sa˜ o Paulo, (FMUSP), Department of Gastroenterology, Gastrointestinal Endoscopy Unit, Sa˜ o Paulo/SP, Brazil. III Sı´rio Libaneˆ s Hospital, Department of Oncology Surgery, Sao Paulo/SP, Brazil. IV University of Wisconsin School of Medicine and Public Health, Department of Surgery, Wisconsin/USA. Email: [email protected] Tel.: 55 11 5585 9119 CASE DESCRIPTION (normal ,14.72, 95th percentile). Manometry showed a lower esophageal sphincter pressure (LES) of 9 mmHg (normal A 46-year-old white woman presented to the clinic in range from 14.3 to 34.5 mmHg), and the contraction amplitude September 2009 with intermittent abdominal epigastric pain of the proximal and middle region was greater than 30 mmHg accompanied by nausea, heartburn and frequent crises of (50.6 mmHg).
    [Show full text]
  • 24-Hour Esophageal Ph Monitoring Prep Instructions Procedure Checklist
    24-Hour Esophageal pH Monitoring Prep Instructions Patient Name: Gastroenterologist: Date/Time of Procedure: _______________________ Arrive: ________________ Report to Main Building, 2nd Floor, Room M2210 Hospital Address: 3800 Reservoir Rd. N.W., Washington, D.C. 20007 Instructions: Attached are detailed instructions as well as a checklist to help you prepare for your procedure. Please read the instructions in their entirety and use the checklist as a guide to help ensure a complete prep for your procedure. Procedure Checklist Before you start: If you have questions concerning your current medications, call 202-444-8541 and select option 4 to speak to a nurse. You may need to make arrangements for a responsible adult or medical transport to drive you home after your procedure. Please see FAQs or call 202-444-8541 and select option 4 to speak to a nurse. Stop medications used for treating reflux and for treating stomach acid problems unless you are told to continue these medications by your physician. o Some medications should be stopped for 1 week prior to the test. These include: Prilosec (omeprazole), Nexium (esomeprazole), Aciphex (rabeprazole), Prevacid (lansoprazole), Protonix (pantoprazole), Zegarid (immediate release omeprazole). o Some medications need to be stopped for 2 days before the test. These include: Zantac (Randitidine), Tagamet (Cimetidine), Axid (Nizatidine), Pepcid (Famotidine). Note that your physician may want you to continue these medications up to and during the test to determine how effective they are in suppressing acid production. If so, please take these medications at your regular time of the day prior to the test and the morning of the test (with a little bit of water) Day of your procedure: Do not eat or drink anything after midnight.
    [Show full text]
  • Peptic Ulcer Disease
    \ Lecture Two Peptic ulcer disease 432 Pathology Team Done By: Zaina Alsawah Reviewed By: Mohammed Adel GIT Block Color Index: female notes are in purple. Male notes are in Blue. Red is important. Orange is explanation. 432PathologyTeam LECTURE TWO: Peptic Ulcer Peptic Ulcer Disease Mind Map: Peptic Ulcer Disease Acute Chronic Pathophysiology Morphology Prognosis Locations Pathophysiology Imbalance Acute severe Extreme Gastric Duodenal gastritis stress hyperacidity between agrresive and defensive Musocal Due to factors increased Defenses Morphology acidity + H. Pylori infection Mucus Surface bicarbonate epithelium barrier P a g e | 1 432PathologyTeam LECTURE TWO: Peptic Ulcer Peptic Ulcer Definitions: Ulcer is breach in the mucosa of the alimentary tract extending through muscularis mucosa into submucosa or deeper. erosi on ulcer Chronic ulcers heal by Fibrosis. Erosion is a breach in the epithelium of the mucosa only. They heal by regeneration of mucosal epithelium unless erosion was very deep then it will heal by fibrosis. Types of Ulcer: 1- Acute Peptic Ulcers ( Stress ulcers ): Acutely developing gastric mucosal defects that may appear after severe stress. Pathophysiology: All new terms mentioned in the diagram are explained next page Pathophysiology of acute peptic ulcer Complication of a As a reult of Due to acute severe stress extreme gastritis response hyperacidity Mucosal e.g. Zollinger- inflammation as a Curling's ulcer Stress ulcer Cushing ulcer Ellison response to an syndrome irritant e.g. NSAID or alcohol P a g e | 2 432PathologyTeam
    [Show full text]
  • Peptic Ulcers
    Peptic Ulcers Peptic ulcer disease (PUD) is a very common ailment in the US, affecting one out of eight persons in their lifetime. Over half a million new cases are diagnosed each year, afflicting some 25 million Americans and costing over $3 billion annually. Recent breakthroughs in the causes of ulcers now give your doctor new ways to treat ulcer disease and help prevent ulcers from ever coming back. Normal Stomach Function To understand how ulcers form, it is first important to understand how the normal stomach and intestines function. The stomach produces acid in response to eating food. This acid serves to start the digestive process by activating the enzyme pepsin, which can then break down proteins in food. In addition, this acid provides a hostile environment that is extremely difficult for most bacteria to survive in. After the food is mixed up and broken into small particles in the stomach, it is released into the first portion of the small intestine, or duodenum. It is here in the small intestine that the actual process of digestion and absorption of nutrients occur. To avoid digesting itself, the stomach and duodenum have special protective mechanisms. A protective coating of mucus covers the inner lining of the stomach and duodenum. There is always a delicate balance between the destructive forces of acid and the protective forces of the stomach and duodenum. This balance is such that just enough acid is made to digest food, but not enough to overwhelm this protective layer. Causes of Peptic Ulcer When the delicate balance between acid and the protective forces is interrupted, ulcers may form.
    [Show full text]